Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP

被引:26
作者
Burton, DW
Geller, J
Yang, M
Jiang, P
Barken, I
Hastings, RH
Hoffman, RM
Deftos, LJ
机构
[1] Univ Calif San Diego, Dept Med, San Diego, CA 92161 USA
[2] San Diego Vet Admin Healthcare Syst, VASDHS, San Diego, CA 92161 USA
[3] AntiCanc Inc, San Diego, CA USA
[4] Prostate Canc Res & Educ Fdn, PCREF, San Diego, CA USA
[5] Univ Calif San Diego, Dept Anesthesiol, San Diego, CA 92161 USA
[6] Univ Calif San Diego, Dept Surg, San Diego, CA 92161 USA
关键词
tumor markers; metastases; bisphosphonates; green fluorescent protein; immunoassay;
D O I
10.1002/pros.20146
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. Prostate cancers (PCas) produce factors that can serve as biomarkers for tumor metastasis and bone progression. Transduced GFP expression by cancer cells can be imaged to monitor therapy. We exploited both concepts by developing a GFP-expressing PCa cell line that expresses PTHrP and studying it in an animal model of malignancy with methods that assess the skeletal progression of this tumor. METHODS. We developed a GFP-producing PCa cell line by stable transduction of PC-3 PCa cells. This PC-3 variant was used to study tumor progression in an immunocompromised mouse model. Skeletal progression of the PCa cells and the effects of pamidronate administration were evaluated radiologically, fluorometrically, and by measurement of serum tumor markers. RESULTS. The PC-3 cells produced extensive bone lesions when injected into the tibia of immunocompromised mice. The skeletal progression of the PC-3 cells could be monitored by GFP optical imaging, X-ray, and by measurements of tumor products in serum, notably PTHrP and OPG. Pamidronate treatment reduced tumor burden as assessed at autopsy by imaging and biomarkers. CONCLUSIONS. Pamidronate treatment exhibited anti-tumor effects that were reflected by decreases in serum PTHrP, OPG, and by GFP and radiological imaging procedures. Imaging of GFP expression enables real-time monitoring of tumor growth in the bone. PTHrP and OPG may be useful as tumor biomarkers for PCa that has metastasized to bone. This novel human PCa model can be used to study the clinical potential of diagnostic and therapeutic modalities in the skeletal progression of PCas. (C) 2004, Wiley-Liss. Inc.
引用
收藏
页码:275 / 281
页数:7
相关论文
共 34 条
[1]  
Ahmadpour OA, 2002, J BONE MINER RES, V17, pS286
[2]   A Nod Scid mouse model to study human prostate cancer [J].
Bastide, C ;
Bagnis, C ;
Mannoni, P ;
Hassoun, J ;
Bladou, F .
PROSTATE CANCER AND PROSTATIC DISEASES, 2002, 5 (04) :311-315
[3]   Bisphosphonates for cancer patients: why, how, and when? [J].
Body, JJ ;
Mancini, I .
SUPPORTIVE CARE IN CANCER, 2002, 10 (05) :399-407
[4]  
Brown JM, 2001, CLIN CANCER RES, V7, P2977
[5]   Osteoprotegerin and rank ligand expression in prostate cancer [J].
Brown, JM ;
Corey, E ;
Lee, ZD ;
True, LD ;
Yun, TJ ;
Tondravi, M ;
Vessella, RL .
UROLOGY, 2001, 57 (04) :611-616
[6]   Metastatic patterns of prostate cancer:: An autopsy study of 1,589 patients [J].
Bubendorf, L ;
Schöpfer, A ;
Wagner, U ;
Sauter, G ;
Moch, H ;
Willi, N ;
Gasser, TC ;
Mihatsch, MJ .
HUMAN PATHOLOGY, 2000, 31 (05) :578-583
[7]   Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial [J].
Conte, PF ;
Latreille, J ;
Mauriac, L ;
Calabresi, F ;
Santos, R ;
Campos, D ;
Bonneterre, J ;
Francini, G ;
Ford, JM .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (09) :2552-2559
[8]  
Corey E, 2003, CLIN CANCER RES, V9, P295
[9]  
Deftos Leonard J., 2000, Cancer, V88, P3002
[10]  
Deftos LJ, 1998, PROSTATE, P23